Sugi Predict
/ Targets
/ MLLT1
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to MLLT1 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Treatment of Acute Lymphoblastic Leukemia in Children |
PHASE3 | COMPLETED |
| Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia |
PHASE3 | UNKNOWN |
| A Prospective Multicenter Clinical Trial of MRD-based Treatment Strategy in Children and Young Adults With AML |
PHASE3 | UNKNOWN |
| CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients |
PHASE3 | RECRUITING |
| A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation |
PHASE1/PHASE2 | RECRUITING |
| Induction Intensification in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia |
PHASE2 | COMPLETED |
| First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia |
PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING |
| A Study of Revumenib and Mezigdomide in People With Leukemia |
PHASE1/PHASE2 | RECRUITING |
| Cord Blood Transplant in Adults With Blood Cancers |
PHASE2 | RECRUITING |
| Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia |
PHASE1/PHASE2 | COMPLETED |
| A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance |
PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING |
| Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia |
PHASE2 | RECRUITING |
| A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene |
PHASE1 | COMPLETED |
| A Phase 1 Study of BMF-500 in Adults With Acute Leukemia |
PHASE1 | ACTIVE_NOT_RECRUITING |
| A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving |
PHASE1 | COMPLETED |
| A Clinical Study of HMPL-506 in Patients With Hematological Malignancies |
PHASE1 | RECRUITING |
| BY002 IIT Study in R/R Acute Leukemia |
PHASE1 | RECRUITING |
| Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome |
PHASE1 | COMPLETED |
| Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA. |
nan | RECRUITING |
| Biomarkers in Samples of Bone Marrow From Patients With Acute Myeloid Leukemia |
nan | COMPLETED |
| Better Leukemia Diagnostics Through AI (BELUGA) |
nan | RECRUITING |
| Role of Biomarkers in Disease Progression in Samples From Patients With Acute Myeloid Leukemia |
nan | COMPLETED |
| Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients |
nan | COMPLETED |
| Functional Pharmacogenomics of Childhood Acute Lymphoblastic Leukemia in Taiwan |
nan | UNKNOWN |
| Triple Negative Adult B-cell Acute Lymphoblastic Leukemia - TRINEG-ALL |
nan | RECRUITING |
| Expression of TET1 Gene in Acute Leukaemia |
nan | UNKNOWN |
| Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells. |
nan | UNKNOWN |
| Clinical and Genomic Registry of MDS in Asia |
nan | UNKNOWN |
| Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid Leukemia |
nan | RECRUITING |
| Study of Non-Myeloablative Haplo-identical Haematopoietic Stem Cell Transplantation in Patients With Haematological Malignancies or Acquired Aplastic Anaemia |
nan | UNKNOWN |
Related proteins — ESM-2 sequence neighbours (a MLLT1 binder may also engage these)